Michael Gelband’s Tenaya Therapeutics TNYA Stock Holding History

Michael Gelband’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-74,715	Closed	-$232K	–	2099
2024 Q2	$232K	Buy	+74,715	New	+$309K	﹤0.01%	1370

Other funds holding TNYA

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Michael Gelband's TNYA Position: Q3 2024 in Review

Michael Gelband sold out of Tenaya Therapeutics (TNYA) in Q3 2024, closing a stake of 74,715 shares — an estimated $232K sold.

Michael Gelband first reported a position in TNYA in Q2 2024 and held it in 1 quarter. The position peaked at $232K in Q2 2024. 95 funds tracked by Wall St. Rank hold TNYA as of Q3 2024.

Michael Gelband reported no remaining Tenaya Therapeutics position as of Q3 2024 after selling out during the quarter.
Michael Gelband sold 74,715 Tenaya Therapeutics shares in Q3 2024, an estimated $232K.
Michael Gelband first reported a position in Tenaya Therapeutics in Q2 2024 and held it in 1 quarter.
Michael Gelband's Tenaya Therapeutics position peaked at $232K in Q2 2024.
95 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.